Citation Impact
Citing Papers
Matrix Protein CCN1 Is Critical for Prostate Carcinoma Cell Proliferation and TRAIL-Induced Apoptosis
2009 Standout
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Prostate cancer
2008
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Epidemiology of Prostate Cancer
2019 Standout
Systematic Review and Meta-analysis of Transurethral Resection of the Prostate Versus Minimally Invasive Procedures for the Treatment of Benign Prostatic Obstruction
2009
Bladder cancer
2016 Standout
Structural Decay of Bone Microarchitecture in Men with Prostate Cancer Treated with Androgen Deprivation Therapy
2010
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Bipolar versus Monopolar Transurethral Resection of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials
2009
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Evaluation of the diagnostic and predictive power of PCA3 in the prostate cancer. A different best cut-off in each different scenario. Preliminary results
2014
Risk of Fracture after Androgen Deprivation for Prostate Cancer
2005
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy
2009
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
2013
Management of Side Effects of Androgen Deprivation Therapy
2011
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Four-Year Outcome of a Prospective Randomised Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate
2009
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
2019
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
2005
Long Noncoding RNA and Cancer: A New Paradigm
2017 Standout
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
2012 Standout
Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review
2012
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
2005 Standout
Bladder Cancer
2020 Standout
LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCER
2005
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
2008
Obesity and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Cancer
2007
Works of J.M. Abascal Junquera being referenced
Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer
2006
Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of Treatment
2003
Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer
2007
Diagnóstico fotodinámico con hexaminolevulinato en el cáncer vesical no músculo invasivo: experiencia del grupo BLUE
2011
The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/ml
2002
Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer
2004
Resección transuretral de próstata bipolar vs monopolar: análisis peroperatorio de los resultados
2006
218 Failure of luteinizing hormone releasing hormone agonist therapy to achieve castration. Does it exist?
2004
Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression
2006
Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: Experience of the BLUE group
2011
Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer
2005